A Phase 1 Sequential Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of CAL-101 in Patients With Select, Relapsed or Refractory Hematologic Malignancies.

Trial Profile

A Phase 1 Sequential Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of CAL-101 in Patients With Select, Relapsed or Refractory Hematologic Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2016

At a glance

  • Drugs Idelalisib (Primary)
  • Indications Acute myeloid leukaemia; B cell lymphoma; Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 08 Dec 2015 Results of post-hoc analysis (n=494) of this and other three trial (see profile 59751, 54699 and 214177) were presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 08 Dec 2015 Results of a pooled post hoc analysis presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
    • 08 Dec 2015 Post hoc results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top